Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis
- 2 December 2011
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 31 (4) , 613-619
Abstract
The clinical response to traditional disease-modifying anti-rheumatic drugs (DMARDs) in indigent South Africans with early rheumatoid arthritis was investigated. A cohort of patients with early (≤2 years) RA who were DMARD-naïve at inception were prospectively assessed for response to DMARDs using the Simplified Disease Activity Index (SDAI) over a 12-month period. Patients with low disease activity (LDA) at 12 months were compared to those with moderate and high disease activity with respect to demographic, clinical, autoantibody and radiographic features. The 171 patients (140 females) had a mean (SD) age of 47.1 (12.4) years, symptom duration of 11.7 (7.1) months and baseline SDAI of 39.4 (16.2). There was a significant overall improvement in the SDAI and its components in the 134 (78.4%) patients who completed the 12 months visit, but only 28.4% of them achieved LDA. The majority of patients (91%) were treated with methotrexate as monotherapy or in combination with chloroquine and/or sulphasalazine. Baseline features that independently predicted a LDA state at 12 months were lower Health Assessment Questionnaire Disability Index (p = 0.023) and a higher haemoglobin level (p = 0.048). Receiver operating characteristic curve analysis showed that the 6-month SDAI was better than the baseline SDAI in predicting the 12-month SDAI (area under the curve of 0.69 vs. 0.52, respectively, p = 0.008). In conclusion, less than a third of the patients achieved a low disease activity at 12 months on traditional DMARDs. Patients who have an inadequate response to traditional DMARDs at 6 months are unlikely to show further improvement on traditional DMARDs at 12 months. These findings underscore the need for better disease control by an aggressive tight control strategy, including intense patient education and biologic therapy.Keywords
This publication has 30 references indexed in Scilit:
- Priority actions for the non-communicable disease crisisThe Lancet, 2011
- Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trialAnnals of the Rheumatic Diseases, 2011
- Disease Progression and Treatment Responses in a Prospective DMARD-naive Seropositive Early Rheumatoid Arthritis Cohort: Does Gender Matter?The Journal of Rheumatology, 2010
- Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trialArthritis Research & Therapy, 2010
- The burden of non-communicable diseases in South AfricaThe Lancet, 2009
- QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countriesAnnals of the Rheumatic Diseases, 2007
- Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity scoreAnnals of the Rheumatic Diseases, 2007
- Therapeutic strategies in early rheumatoid arthritisBest Practice & Research Clinical Rheumatology, 2005
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Thrombocytosis of active rheumatoid disease.Annals of the Rheumatic Diseases, 1983